When considering the performance of the pharmaceuticals sector, an investor is almost always challenged with the question of definitions. Simply put, what exactly is a pharmaceutical company and where are the lines between "biotech," "specialty pharmaceutical," "generic," and regular ol' pharmaceutical companies? (For related reading, see Evaluating Pharmaceutical Companies.)
Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

Leaving aside the issue of nomenclature, and acknowledging that there is some subjectivity involved in who is included or left out, this was actually a fairly strong year for the sector. True, fewer people are seeing the doctor, high unemployment means fewer people on insurance rolls, and overall health care spending has not been very strong. Nevertheless, the market has warmed to these stocks, as the iShares Dow Jones U.S. Pharmaceuticals ETF (ARCA:IHE) has handily beaten the market this year and risen by a solid mid-teens percentage.

Relatively Little Red
One of the first things that jumps about this sector's 2011 performance is the relatively small number of losers. Forest Labs (NYSE:FRX) and Novartis (NYSE:NVS) both seem likely to end the year in the red, with Forest Labs really suffering from Wall Street's doubts regarding the company's ability to replace soon-to-be-lost sales from patent expirations. Warner Chilcott (Nasdaq:WCRX) has done even worse, though, with the stock returning a loss of more than 30%, as the company lost exclusivity on osteoporosis drug Actonel, saw a dermatology drug distribution agreement end, and faced higher than expected costs in converting a manufacturing plant into a distribution center.

Some Big Winners
On the green side of the fence, there were some surprisingly successful stories in the drug sector this year. Valeant Pharmaceuticals (NYSE:VRX) has been aggressive in restructuring its operations and the stock has returned nearly 60% so far this year. Even the goliaths have gotten into the act; Bristol-Myers Squibb (NYSE:BMY) and GlaxoSmithKline (NYSE:GSK) have risen over 30 and 20% respectively, this year.

Bristol-Myers not only has an encouraging pipeline, but the company has delivered better-than-expected sales of some key new drugs, while also paying an attractive dividend. Glaxo, meanwhile, has coupled good emerging markets and vaccine exposure, and has perhaps benefited from being too badly beaten-down in times past.

Are the Gain Already Bagged?
The downside to this strong 2011 performance may be that it has robbed some of the momentum from 2012. Many stocks have already traded up on the expected benefits of new product approvals and further cost-cutting, leaving many companies hard pressed to deliver more red meat to an always growth-hungry market.

The Bottom Line
Looking into the next year, then, investors may be better served shopping in the scratch-and-dent aisles. Forest Labs, for instance, has a long history of defying the skeptics and finding ways of rebuilding its revenue. Novartis has a well-integrated suite of businesses and an undemanding valuation, while Merck (NYSE:MRK) may be undervalued for its earnings quality. If there is a 2011 winner to bet on for 2012, it may well be Pfizer (NYSE:PFE). Though this stock has climbed nicely already (up more than 20% for 2011), the stock still looks undervalued for its long-term potential. (For a quick introduction to biotechnology's place in the market, read A Primer On The Biotech Sector.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    How to Find Quality Stocks Amid the Wreckage

    Finding companies with good earnings and hitting on all cylinders in this environment, although possible, is not easy.
  2. Investing News

    What You Can Learn from Carl Icahn's Mistakes

    Carl Icahn has been a stellar performer in the investment world for decades, but following his lead these days could be dangerous.
  3. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  4. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  5. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  6. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  7. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  8. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  9. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  10. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center